Here, we report a case of a 68-year-old female with metastatic NSCLC who responded well to treatment with anlotinib and sintilimab, with RET fusion and positive PD-L1 expression, and to our knowledge, this is the first such clinical case report. The gene discussed is RET; the disease is non-small cell lung carcinoma.